Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Adding More Pediatric Data To Labeling

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA divisions will be more aggressive in requiring pediatric data be included in labeling following recommendation by Office of New Drugs Director Jenkins. However, the added language in labeling will not necessarily clarify whether a drug is safe for use in children, Office of Pediatric Therapeutics Director Murphy notes.
Advertisement

Related Content

Pediatric Adverse Event Reporting Could Improve With Claims Database Analysis
Pediatric Adverse Event Reporting Could Improve With Claims Database Analysis
Pediatric Adverse Event Reporting Could Improve With Claims Database Analysis
FDA Approves Antidepressant "Black Box" Class Labeling
Pediatric Exclusivity Studies Will Be Included In Labeling, FDA Says
Pediatric Exclusivity Studies Will Be Included In Labeling, FDA Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS061548

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel